1. Biondi B, Wartofsky L. Treatment with Thyroid Hormone. Endocrine Reviews, published ahead of print: doi:10/1210/er.2013-1083; 2014;35:433–512.
2. Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab. 2008;93:1167–9.
3. Carayon P, Thomnas-Morvan C, Castan E, Tubiana M. Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab. 1980;51:915–20.
4. Derwahl M, Broecker M, Kraiem Z. Thyrotropin may not be the dominant growth factor in benign and malignant thyroid nodules. J Clin Endocrinol Metab. 1999;84:829–34.
5. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91:4295–301.